Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria: * Metastatic Pancreatic Ductal Adenocarcinoma with histological or cytological proof * Age ≥18 years * At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 outside any previously irradiated area * Failure of first line FOLFIRINOX (Progressive disease during therapy of within 3 months +/- 15 days) * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 * Life expectancy ≥12 weeks * Negative serology (HIV, hepatitis B and C) * Adequate organs function * Proven Post-menopausal status or negative urinary or serum pregnancy test * Woman of childbearing potential and male patients must agree to use adequate contraception fo the duration of the trial and up to 6 months after completing treatment * Patients affiliated to the social security system * Patient must have signed a written informed consent form Exclusion Criteria: * Any other primary tumor or secondary malignancy except basal cell carcinoma of skin or in situ carcinoma of the cervix uteri * Known cerebral metastasis * Uncontrolled severe infections * Patients with Kaposi's sarcoma * Peripheral neuropathy exceeding grade 2 on Common Terminology Criteria for Adverse Events (CTCAE) v5.0 * Previous treatment with taxane and/or gemcitabine (for pancreas cancer only) * Patients with known allergy or severe hypersensitivity to any trial drug or drug excipient * Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment * Patients unable to comply with trial obligations for geographic, social or physical reasons, or who are unable to understand the purpose and procedures of the trial * Participation in another clinical trial within 14 days prior to randomization * Patients deprived of liberty or under legal protection measures or patients whose willingness to participate in the trial may be unduly influenced